- Home
- PETZ vs NRSN Comparison
PETZ vs NRSN Comparison
Compare PETZ & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | NRSN |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 14.2M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PETZ | NRSN |
|---|---|---|
| Price | $1.31 | $6.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 388.9K | 385.5K |
| Earning Date | 04-20-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.25 |
| 52 Week High | $1.83 | $7.50 |
Technical Indicators
Market Signals| Indicator | PETZ | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 89.19 |
| Support Level | $1.01 | $0.63 |
| Resistance Level | $1.81 | N/A |
| Average True Range (ATR) | 0.13 | 0.46 |
| MACD | 0.00 | 0.74 |
| Stochastic Oscillator | 38.06 | 89.26 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.